로딩 중…
StockDiggingStockDigging

Revvity, Inc.

RVTY· NYSE
$115.26+2.44%
2026-08-03

Financials

Valuation Metrics

Revvity, Inc.'s Market Cap is $12.86B. At end of 2025 it was $10.95B. Ranked #809 of 3,112 in US market (top 26%), #562 of 1,667 on NYSE (top 34%), #51 of 206 in Health Care Equipment & Services (top 25%) by Market Cap.

Investment Metrics(as of 2026-08-03)

MetricValue
Size
Market Cap$12.86B
Revenue$2.90B
Net Income$241M
Total Assets$12.00B
Net Assets$7.18B
Employees11,000
Value
P/E53.36x
P/B1.79x
P/S4.43x
EV/EBITDA19.86x
FCF Yield3.84%
Profitability
ROE3.35%
ROA2.01%
Op. Margin12.41%
Revenue Growth6.97%
Earnings Growth-3.60%
Financial Health
Debt Ratio67.02%
Total Debt$3.35B
FCF$494M
Cash$860M
Current Ratio1.72x
Net Debt/EBITDA3.22x
Dividend
Div. Yield0.25%
Div. Growth3.21%
Performance
1Y Return30.81%
1M Return1.32%
From 52W High-2.57%
1Y MDD-30.14%
Trading
Volume2,064,761 shares
Trading Value$237M
Per Share
EPS$2.13
BPS$64.04

Company Info

CEO Dr. Prahlad R. Singh Ph.D.
Employees 11,000
HQ Waltham, United States

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.